CLN-049
CLN-049-001
Phase 1 small_molecule active
Quick answer
CLN-049 for Relapsed/Refractory Acute Myeloid Leukemia (AML) is a Phase 1 program (small_molecule) at Cullinan Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cullinan Therapeutics
- Indication
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active